Prostate cancer chemoprevention

Update of the prostate cancer prevention trial findings and implications for clinical practice

Jamey A. Sarvis, Ian M. Thompson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This article updates the findings of the Prostate Cancer Prevention Trial (PCPT) based on recent publications and reviews of the PCPT. New evidence shows that finasteride reduces the overall risk of prostate cancer by 30% and reduces the risk of clinically significant prostate cancer, including high-grade tumors. For tumors with Gleason scores of ≤ 6, men in the finasteride arm had a relative risk reduction (RRR) of 34% (RR, 0.66; 95% CI, 0.55 - 0.80; P ≤ 0.0001); tumors with Gleason scores of ≤ 7 had an RRR of 27% (RR, 0.73; 95% CI, 0.56 - 0.96; P = 0.02). The effect of finasteride on sexual function appears to be minimal as men on finasteride had an average 3.21 point increase on the 100 point Sexual Activity Scale compared with men on placebo. With an excellent safety profile and minimal side effects, men aged 55 years or older should be informed of the opportunity to reduce their risk of prostate cancer with finasteride.

Original languageEnglish (US)
Pages (from-to)529-532
Number of pages4
JournalCurrent Oncology Reports
Volume10
Issue number6
DOIs
StatePublished - 2008

Fingerprint

Finasteride
Chemoprevention
Prostatic Neoplasms
Neoplasm Grading
Risk Reduction Behavior
Neoplasms
Sexual Behavior
Placebos
Safety

ASJC Scopus subject areas

  • Oncology

Cite this

Prostate cancer chemoprevention : Update of the prostate cancer prevention trial findings and implications for clinical practice. / Sarvis, Jamey A.; Thompson, Ian M.

In: Current Oncology Reports, Vol. 10, No. 6, 2008, p. 529-532.

Research output: Contribution to journalArticle

@article{e650031035a54cf391600e7911963971,
title = "Prostate cancer chemoprevention: Update of the prostate cancer prevention trial findings and implications for clinical practice",
abstract = "This article updates the findings of the Prostate Cancer Prevention Trial (PCPT) based on recent publications and reviews of the PCPT. New evidence shows that finasteride reduces the overall risk of prostate cancer by 30{\%} and reduces the risk of clinically significant prostate cancer, including high-grade tumors. For tumors with Gleason scores of ≤ 6, men in the finasteride arm had a relative risk reduction (RRR) of 34{\%} (RR, 0.66; 95{\%} CI, 0.55 - 0.80; P ≤ 0.0001); tumors with Gleason scores of ≤ 7 had an RRR of 27{\%} (RR, 0.73; 95{\%} CI, 0.56 - 0.96; P = 0.02). The effect of finasteride on sexual function appears to be minimal as men on finasteride had an average 3.21 point increase on the 100 point Sexual Activity Scale compared with men on placebo. With an excellent safety profile and minimal side effects, men aged 55 years or older should be informed of the opportunity to reduce their risk of prostate cancer with finasteride.",
author = "Sarvis, {Jamey A.} and Thompson, {Ian M.}",
year = "2008",
doi = "10.1007/s11912-008-0080-1",
language = "English (US)",
volume = "10",
pages = "529--532",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Prostate cancer chemoprevention

T2 - Update of the prostate cancer prevention trial findings and implications for clinical practice

AU - Sarvis, Jamey A.

AU - Thompson, Ian M.

PY - 2008

Y1 - 2008

N2 - This article updates the findings of the Prostate Cancer Prevention Trial (PCPT) based on recent publications and reviews of the PCPT. New evidence shows that finasteride reduces the overall risk of prostate cancer by 30% and reduces the risk of clinically significant prostate cancer, including high-grade tumors. For tumors with Gleason scores of ≤ 6, men in the finasteride arm had a relative risk reduction (RRR) of 34% (RR, 0.66; 95% CI, 0.55 - 0.80; P ≤ 0.0001); tumors with Gleason scores of ≤ 7 had an RRR of 27% (RR, 0.73; 95% CI, 0.56 - 0.96; P = 0.02). The effect of finasteride on sexual function appears to be minimal as men on finasteride had an average 3.21 point increase on the 100 point Sexual Activity Scale compared with men on placebo. With an excellent safety profile and minimal side effects, men aged 55 years or older should be informed of the opportunity to reduce their risk of prostate cancer with finasteride.

AB - This article updates the findings of the Prostate Cancer Prevention Trial (PCPT) based on recent publications and reviews of the PCPT. New evidence shows that finasteride reduces the overall risk of prostate cancer by 30% and reduces the risk of clinically significant prostate cancer, including high-grade tumors. For tumors with Gleason scores of ≤ 6, men in the finasteride arm had a relative risk reduction (RRR) of 34% (RR, 0.66; 95% CI, 0.55 - 0.80; P ≤ 0.0001); tumors with Gleason scores of ≤ 7 had an RRR of 27% (RR, 0.73; 95% CI, 0.56 - 0.96; P = 0.02). The effect of finasteride on sexual function appears to be minimal as men on finasteride had an average 3.21 point increase on the 100 point Sexual Activity Scale compared with men on placebo. With an excellent safety profile and minimal side effects, men aged 55 years or older should be informed of the opportunity to reduce their risk of prostate cancer with finasteride.

UR - http://www.scopus.com/inward/record.url?scp=58649114670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58649114670&partnerID=8YFLogxK

U2 - 10.1007/s11912-008-0080-1

DO - 10.1007/s11912-008-0080-1

M3 - Article

VL - 10

SP - 529

EP - 532

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 6

ER -